MedTrace Logo

Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans

NCT02796001 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-06-06

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the relationship between rhinovirus specific T-cell immunity and the human host response to primary rhinovirus challenge and subsequent secondary challenge with either homologous or heterologous rhinovirus serotypes.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

human rhinovirus

human rhinovirus

OTHER

no intervention

4 volunteers were not re-challenged and did not participate in the second challenge

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Ronald Turner, MD · Univ of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2020-05-01
Completion
2020-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02796001 on ClinicalTrials.gov